Search Results
Your search for ,now matches 6673 pages
Showing 4151 - 4200Understanding the Role of Immunotherapy for Lung Cancer: A Paradigm Shift for the Better
“Immunotherapy for lung cancer is a paradigm shift. I would never have thought when I started my career taking care of lung cancer patients in the mid 1990s that we’d now be substituting chemotherapy with an antibody immunotherapy in 2017. It’s incredible,” commented Roy S. Herbst, MD, PhD, Chief...
Early Biomarker Algorithm May Predict Graft-vs-Host Disease Occurrence
Researchers at Mount Sinai Health System have discovered a way to predict whether patients with blood cancer who received a bone marrow transplant will develop graft-vs-host disease, according to a study published by Hartwell et al in JCI (The Journal of Clinical...
2017 GU Cancers Symposium: Blood Test Uncovers Potential New Treatment Targets in Advanced Prostate Cancer
Analysis of free-floating cancer DNA from blood samples has yielded leads for new prostate cancer treatment targets. Using a commercially available “liquid biopsy” test in patients with advanced prostate cancer, researchers found a number of genetic changes in cell-free, circulating...
Cancer Survivors Find Online and Telephone Communication With Health-Care Professionals Beneficial
Researchers from the School of Health Sciences at the University of Surrey have completed the first-ever systematic review of cancer survivors’ experience of online and telephone telehealth interventions in cancer care, a new study by Cox et al in the Journal of Medical Internet...
Albert H. Owens, Jr, MD, Pioneering Johns Hopkins Oncologist, Dies
Albert H. Owens, Jr, MD, a Johns Hopkins oncologist who played a leadership role in developing oncology as a scientific discipline and clinical specialty—and who also served as President of The Johns Hopkins Hospital—died January 13 at the age of 90. In the 1960s, oncology was not a word that...
Co-Discoverer of the Philadelphia Chromosome, Peter Nowell, MD, Dies
Peter Nowell, MD, was a pathologist at the University of Pennsylvania studying leukemia cells under a microscope when he happened to wash his slides with tap water instead of laboratory solution. Viewing the newly cleaned slides under a microscope, he saw that the water had caused the cell’s...
Link Between Alcohol Intake and Increased Risk for Melanoma
Although alcohol consumption is associated with increasing the risk of many cancers, including liver, pancreatic, colon, rectal, and breast, the link between alcohol and higher risk of melanoma is equivocal. Now, a large prospective study by Andrew Rivera, MD, of Harvard Medical School, Boston, and ...
Kerry and Simone Vickar Family Foundation Commits $2 Million for Levine Cancer Institute Hematologic Oncology Chair
Carolinas HealthCare System has announced a $2 million commitment from the Kerry and Simone Vickar Family Foundation in support of academic and research efforts at the Levine Cancer Institute in Charlotte, North Carolina. The funds will be designated to establish an endowed chair in their name: The ...
Richard M. Goldberg, MD, Named Director of West Virginia University Cancer Institute
Richard M. Goldberg, MD, an expert in gastrointestinal cancer, has been named the new Director of the West Virginia University Cancer Institute. Dr. Goldberg will be coming to West Virginia University from The Ohio State University’s Wexner Medical Center, where he currently serves as Klotz Family ...
NCCN Working Group on Value Tools Presents Preliminary Findings and Recommendations
Over the past several years, the introduction of decision-making tools for patients from major cancer organizations, including ASCO and the National Comprehensive Cancer Network® (NCCN®), has been news, applauded as a step toward more patient-centered care and featured at many meetings. Next steps, ...
On the Horizon: New Tools for Prostate Cancer
The field of prostate cancer is being energized by discoveries in genetics, novel imaging techniques, and the potential of checkpoint inhibitors in the treatment of prostate cancer. Not all of these advances are currently clinically actionable, but all have the potential to change clinical...
Women of Indigenous Communities Prefer Self-Screening for Cervical Cancer
Cervical cancer is a preventable disease if detected on time, but it remains one of the leading causes of cancer deaths among women in Latin America, particularly women of poor and indigenous communities. A new study by the University of Michigan published by Gottschlich et al in the Journal of...
Intentional Weight Loss in Postmenopausal Women May Be Linked to Reduced Endometrial Cancer Risk
Although many studies have linked obesity with an increased risk for endometrial cancer, information about the influence of weight loss on the cancer in postmenopausal women has been limited. Now, a study by Luo et al evaluating the association of weight change and endometrial cancer risk among...
Double Your Impact: Donate to the Conquer Cancer Foundation Today
If you’ve never given to the Conquer Cancer Foundation (CCF), now’s the time. An anonymous donor has generously offered to match—dollar for dollar—first-time gifts to CCF. Funds raised through the challenge will be used to support CCF’s vital work, including funding clinical and translational...
Expert Point of View: Steven D. Gore, MD, and Rami Komrokji, MD
Steven D. Gore, MD, Director of Hematologic Malignancies at Yale School of Medicine, New Haven, Connecticut, applauded Dr. Stein for “accruing a terrible patient population, mutation-wise” and called the preliminary findings for the benefit of enasidenib in patients with ASXL1 mutations...
Selected Abstracts From the 2016 ASH Annual Meeting
Here are several abstracts selected from the proceedings of this year’s American Society of Hematology (ASH) Annual Meeting & Exposition, highlighting newer therapeutics in several different types of non-Hodgkin lymphomas (NHLs), including mantle cell lymphoma and marginal zone lymphoma. For...
Studies Advance the Use of PD-1 Blockade in Classical Hodgkin Lymphoma
Classical Hodgkin lymphoma is one of the malignancies most susceptible to treatment with monoclonal antibodies targeting the programmed cell death protein (PD-1). Nivolumab (Opdivo) has been approved by the U.S. Food and Drug Administration (FDA) for use in patients with relapsed/refractory...
Expert Point of View: Amber Orman, MD
Amber Orman, MD, of the Department of Radiation Oncology, Breast Section, at Moffitt Cancer Center in Tampa, Florida, who was not involved in this study, said: “This study provides guidance when deciding how best to integrate postmastectomy reconstruction and radiation therapy. This is an area...
Autologous Breast Reconstruction Associated With Fewer Complications and Failures Than Implants in Women Who Have Received Radiation
Postmastectomy radiation is becoming more commonly used to treat breast cancer, and at the same time, there is an increasing trend among women to have breast reconstruction. Until now, oncologists have had little evidence on what the best reconstruction options are in women who require radiation...
Randomized Trial Demonstrates Benefit of Scalp-Cooling in Prevention of Chemotherapy-Induced Hair Loss
A scalp-cooling device was found safe and effective in preventing chemotherapy-induced hair loss in women undergoing adjuvant treatment for breast cancer in an interim analysis of the first prospective, randomized trial of a modern scalp-cooling system. The study was presented at the 2016 San...
Expert Point of View: Melinda L. Telli, MD
Melinda L. Telli, MD, Assistant Professor of Medicine at Stanford University Medical Center, Palo Alto, commented on this topic for The ASCO Post. She said the results of the two studies reinforce what has been emerging about the prognostic impact of tumor-infiltrating lymphocytes. “We have known...
ECCO 2017: Pembrolizumab Shows Activity in Mucosal Melanoma in Multiple KEYNOTE Studies
Three clinical trials of the immunotherapy pembrolizumab (Keytruda) have shown that it is active against a rare subtype of skin cancer, mucosal melanoma. The findings were presented by Butler et al at the 2017 European Cancer Congress (ECCO) (Abstract 1142). Until now, mucosal melanoma has often...
The Cost of a Patient’s Last Ride
It was a call from a referring physician who wanted the patient to be transferred to our major academic center. The patient had a history of a lethal malignancy in a very advanced stage. The patient was already outside the bell curve, for she had survived far longer than expected for a malignancy...
Dual Inhibition Proves Effective for BRAF-Mutated Colorectal Tumors
In patients with metastatic colorectal cancer who have mutations in BRAF V600, the addition of the BRAF inhibitor vemurafenib (Zelboraf) to cetuximab (Erbitux) and irinotecan significantly improved progression-free survival, results of the phase II Southwest Oncology Group (SWOG) 1406 trial have...
Postmenopausal Normal-Weight Women With Poor Metabolic Health May Have Higher Risk for Colorectal Cancer
Few studies have explored the association between metabolic phenotype and colorectal cancer incidence in normal-weight individuals. Now, a study comparing the risk of colorectal cancer in normal-weight postmenopausal women with a metabolically unhealthy phenotype vs those with a metabolically...
Immunotherapy 2.0 Named Advance of the Year in ASCO's Report
A growing number of patients with cancer are benefiting from research advances in immunotherapy, leading ASCO to name immunotherapy as the Society's Advance of the Year for a second year in a row. Released today, Clinical Cancer Advances 2017: ASCO's Annual Report on Progress Against Cancer...
Diagnosis and Management of AML in Adults: 2017 European LeukemiaNet Recommendations From an International Expert Panel
An international panel of experts has released updated evidence-based and expert opinion–based recommendations for the diagnosis and treatment of acute myeloid leukemia (AML) in adults. The recommendations were issued by the European LeukemiaNet (ELN) and published by Döhner et al in...
SWOG Launches National Immunotherapy Clinical Trial for Rare Cancers
People with rare cancers now have the option of joining a national clinical trial testing leading-edge immunotherapies for a wide variety of tumor types. It’s the first federally funded immunotherapy trial devoted to rare cancers. Despite their name, rare cancers make up more than 20% of...
Martin J. Edelman, MD, Joins Fox Chase Cancer Center as Chair of the Department of Hematology/Oncology
Martin J. Edelman, MD, an expert in the research and treatment of lung cancer, has joined Fox Chase Cancer Center, Philadelphia, as Chair of the Department of Hematology/Oncology. He will also serve as Deputy Cancer Center Director for Clinical Research, leading the effort to integrate discoveries ...
What Have We Got to Lose?
Tuesday morning was the regular time for the departmental meeting—an opportunity to discuss cases, troubleshoot, debrief, and expedite the necessary allied health referrals. As usual, patient cases were being discussed in alphabetical order of the attending oncologist. We were already three...
An Ovarian Cancer Survivor’s Story
Ovarian cancer, the deadliest of gynecologic cancers, is usually diagnosed after the disease has spread. Susan Evans was a secondary English and remedial reading teacher for 32 years in Bradford, Pennsylvania. She was on several advisory boards and was recognized by the Pennsylvania Senate and...
How ASCO’s New Health Policy Fellowship Program Is Helping Shape Future Cancer Care Policy
In October 2015, ASCO launched the Health Policy Fellowship program to help the next generation of oncologists with an interest in health policy to develop the skills and experience necessary to achieve their goals and shape cancer care policy in an increasingly complicated and diverse care...
New President of the Skin Cancer Foundation Emphasizes Public Education to Reduce Skin Cancer Incidence and Deaths
The statistics on the rising rates of skin cancer are alarming. According to the Skin Cancer Foundation, each year over 5.4 million cases of nonmelanoma skin cancer are treated in more than 3.3 million people, and an additional 76,380 people are diagnosed with the deadliest form of skin cancer,...
Expert Point of View: Kanti R. Rai, MD
Kanti R. Rai, MD, Professor of Medicine, Hofstra Northwell School of Medicine, New Hyde Park, New York, commented on these study findings. “I congratulate the investigators for a work done with discipline, excellent collaboration, and speed.” “All of us who have become familiar with ibrutinib...
Ibrutinib: A Potential Option for Chronic Graft-vs-Host Disease?
Currently, there is no U.S. Food and Drug Administration (FDA)-approved therapy for chronic graft-vs-host disease—a life-threatening consequence of stem cell or bone marrow transplant—that has not responded to corticosteroids, but this may be about to change. Ibrutinib (Imbruvica) achieved...
Survivorship Symposium 2017: Almost Half of Partners and Caregivers of Young Breast Cancer Survivors Experience Long-Lasting Anxiety
While evidence is mounting on the physical and emotional challenges many cancer caregivers experience, few studies have addressed the experience of partners of young adults with cancer. Now, a new study evaluating the psychosocial concerns and mental health in the partners of young survivors of...
Addressing Discrimination and Bias in Medical Education
“As a medical student, I often felt marginalized from my medical community. I have been told that my name is ‘not American,’ fallen prey to being confused for support staff such as a janitor (even while wearing my white coat) and been asked questions like, ‘Where are you really from?’ or ‘How old...
Diamonds Are Forever, Tyrosine Kinase Inhibitors Are Not?
Sir Donald Munger: “You have been on holiday, I understand. Relaxing, I hope?” James Bond: “Oh, hardly relaxing, but most satisfying.” (Diamonds Are Forever) As tyrosine kinase inhibitors became the mainstay of therapy for patients with chronic myeloid leukemia (CML), our assumption has been that...
Safety of Stopping Imatinib in CML With Undetectable Minimal Residual Disease for at Least 2 Years
As reported in the Journal of Clinical Oncology by Gabriel Etienne, MD, PhD, of the Institut Bergonié, Bordeaux, and colleagues, long-term follow-up in the French Stop Imatinib (STIM1) study indicates that imatinib can be safely stopped in patients with chronic myeloid leukemia (CML) with...
Nivolumab in Squamous Cell Carcinoma of the Head and Neck in CheckMate 141: Game Not Over
Most patients with squamous cell carcinoma of the head and neck present with locally advanced disease. With combined-modality approaches, the chance of cure ranges from < 50% to up to 80%, depending on the site, stage, and other risk factors, such as human papillomavirus (HPV) status. When...
Optimizing Access to Fertility Preservation Options
Ensuring that people with cancer understand how cancer treatment could affect their fertility and what options are available for preserving fertility were widely recognized as top priorities by attendees of the 2016 Oncofertility Conference in Chicago. As detailed at the conference, means of...
Managing Breast Cancer in a Pregnant Patient
“One of the most challenging oncologic situations that I face as a clinician is the diagnosis of breast cancer in a young pregnant patient,” Jacqueline Jeruss, MD, PhD, Director of the Breast Care Center at the University of Michigan Comprehensive Cancer Center, Ann Arbor, told the more than 250...
Selected Abstracts From the 2016 San Antonio Breast Cancer Symposium
Each year, The ASCO Post asks Jame Abraham, MD, Director of the Breast Oncology Program at Taussig Cancer Institute and Co-Director of the Cleveland Clinic Comprehensive Breast Cancer Program, to give his picks for the most important research presented at the San Antonio Breast Cancer Symposium....
Expert Point of View: Howard A. “Skip” Burris, MD
Howard A. “Skip” Burris, MD, President of Clinical Operations and Chief Medical Officer at Sarah Cannon Research Institute, Nashville, commented on the poster presentation for The ASCO Post. He said the results “fit the whole paradigm” that is desired for triple-negative breast cancer, which is to ...
Osimertinib Significantly Improves Survival for Patients With Non–Small Cell Lung Cancer
For patients with epidermal growth factor receptor (EGFR) T790M–positive non–small cell lung cancer (NSCLC), osimertinib (Tagrisso) demonstrated clinically superior efficacy over pemetrexed (Alimta) plus a platinum agent, with a 70% reduction in the risk of disease progression, according to the...
Precision Medicine Analysis of 203 Pediatric Brain Tumors May Advance Diagnosis and Treatment
Precision medicine has advanced to the point where it can now impact the care of a majority of children with brain tumors, a new study by investigators at Dana-Farber/Boston Children's Cancer and Blood Disorders Center suggests. In the largest clinical study to date of genetic abnormalities in...
2017 GI Cancers Symposium: Watch-and-Wait Approach for Rectal Cancer Appears an Option for More Patients
Real-world data from a large observational study suggests that omitting surgery in strictly selected patients with a clinical complete response does not compromise outcomes in rectal cancer. The 3-year survival rate among patients who received “watch-and-wait” care after initial cancer...
Prostate Cancer Treatment Rates Drop, Reflecting Change in Screening Recommendations
As some national guidelines now recommend against routine prostate cancer screening, the overall rate of men receiving treatment for the disease declined 42% between 2007 and 2012, a new study published by Borza et al in Health Affairs found. The decline reflects efforts to decrease overdiagnosis...
Has the Affordable Care Act Reduced Socioeconomic Disparities in Cancer Screening?
Out-of-pocket expenditures are thought to be a significant barrier to receiving cancer preventive services, especially for individuals of lower socioeconomic status. A new study published by Cooper et al in Cancer looked at how the Affordable Care Act (ACA), which eliminated such out-of-pocket...
NCI-Designated Cancer Centers Issue Statement in Support of New CDC Recommendations on HPV Vaccination
The 69 National Cancer Institute (NCI)-designated cancer centers have issued a joint statement in support of recently revised recommendations from the Centers for Disease Control and Prevention (CDC) to improve national vaccination rates for human papillomavirus (HPV). According to the CDC,...
